Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Tax Provisions (2017 - 2021)

Celldex Therapeutics (CLDX) has 4 years of Tax Provisions data on record, last reported at $27000.0 in Q4 2021.

  • For Q4 2021, Tax Provisions fell 97.0% year-over-year to $27000.0; the TTM value through Dec 2021 reached $727000.0, up 3.86%, while the annual FY2021 figure was -$200000.0, 82.86% up from the prior year.
  • Tax Provisions reached $27000.0 in Q4 2021 per CLDX's latest filing, down from $900000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $900000.0 in Q4 2020 and bottomed at -$19.1 million in Q4 2017.
  • Average Tax Provisions over 4 years is -$3.5 million, with a median of -$200000.0 recorded in 2020.
  • The widest YoY moves for Tax Provisions: up 97.0% in 2021, down 97.0% in 2021.
  • A 4-year view of Tax Provisions shows it stood at -$19.1 million in 2017, then skyrocketed by 100.18% to $35000.0 in 2018, then skyrocketed by 2471.43% to $900000.0 in 2020, then crashed by 97.0% to $27000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $27000.0 in Q4 2021, $900000.0 in Q4 2020, and -$200000.0 in Q2 2020.